Robert Olivares

3.1k total citations · 1 hit paper
21 papers, 2.3k citations indexed

About

Robert Olivares is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Robert Olivares has authored 21 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Robert Olivares's work include Lymphoma Diagnosis and Treatment (6 papers), Lung Cancer Treatments and Mutations (4 papers) and Viral-associated cancers and disorders (3 papers). Robert Olivares is often cited by papers focused on Lymphoma Diagnosis and Treatment (6 papers), Lung Cancer Treatments and Mutations (4 papers) and Viral-associated cancers and disorders (3 papers). Robert Olivares collaborates with scholars based in United States, France and United Kingdom. Robert Olivares's co-authors include Dana Hilt, Juha E. Jääskeläinen, Manfred Westphal, Peter C. Warnke, Enoch Bortey, Zvi Ram, Patrick Delavault, Ian R. Whittle, Pierre Ducimetière and Jean Claude and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Robert Olivares

21 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A phase 3 trial of local chemotherapy with biodegradable carmustine(BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma

2003 980 citations Manfred Westphal, Dana Hilt et al. Neuro-Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Olivares United States	11	886	594	574	514	399	21	2.3k
Alexander Lossos Israel	30	691 0.8×	636 1.1×	630 1.1×	656 1.3×	244 0.6×	110	2.9k
Won Jun Kang South Korea	29	295 0.3×	568 1.0×	342 0.6×	712 1.4×	167 0.4×	148	2.9k
John A. Boockvar United States	37	1.3k 1.4×	490 0.8×	527 0.9×	856 1.7×	643 1.6×	175	4.0k
M. Bamberg Germany	34	1.1k 1.3×	1.4k 2.4×	746 1.3×	845 1.6×	465 1.2×	223	3.9k
Herbert H. Engelhard United States	29	1.2k 1.3×	471 0.8×	283 0.5×	759 1.5×	425 1.1×	88	2.8k
Kyung‐Sub Moon South Korea	30	831 0.9×	513 0.9×	560 1.0×	639 1.2×	693 1.7×	159	3.1k
Lan Coffman United States	21	592 0.7×	291 0.5×	811 1.4×	844 1.6×	160 0.4×	48	2.8k
Jacob C. Easaw Canada	24	950 1.1×	623 1.0×	437 0.8×	598 1.2×	328 0.8×	87	2.2k
A D Pearson United Kingdom	29	706 0.8×	377 0.6×	686 1.2×	1.1k 2.2×	396 1.0×	69	3.0k
Herbert B. Newton United States	29	1.2k 1.3×	632 1.1×	574 1.0×	1.2k 2.4×	423 1.1×	86	3.0k

Countries citing papers authored by Robert Olivares

Since Specialization

Citations

This map shows the geographic impact of Robert Olivares's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Olivares with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Olivares more than expected).

Fields of papers citing papers by Robert Olivares

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Olivares. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Olivares. The network helps show where Robert Olivares may publish in the future.

Co-authorship network of co-authors of Robert Olivares

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Olivares. A scholar is included among the top collaborators of Robert Olivares based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Olivares. Robert Olivares is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nordon, Clémentine, Mark Belger, Javier Jiménez, et al.. (2017). Trial exclusion criteria and their impact on the estimation of antipsychotic drugs effect: A case study using the SOHO database. Schizophrenia Research. 193. 146–153. 7 indexed citations

Trask, Peter C., Jianmin Wang, Robert Olivares, et al.. (2015). Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis. Journal of Oncology Pharmacy Practice. 22(5). 666–678. 7 indexed citations

Trask, Peter C., Jianmin Wang, Robert Olivares, et al.. (2014). Randomized Controlled Trials in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis. Clinical Lymphoma Myeloma & Leukemia. 15(4). 199–207. 1 indexed citations

Colosia, Ann, Annete Njue, Peter C. Trask, et al.. (2014). Clinical Efficacy and Safety in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Systematic Literature Review. Clinical Lymphoma Myeloma & Leukemia. 14(5). 343–355.e6. 10 indexed citations

Njue, Annete, Ann Colosia, Peter C. Trask, et al.. (2014). Clinical Efficacy and Safety in Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Literature Review. Clinical Lymphoma Myeloma & Leukemia. 15(1). 1–12.e7. 7 indexed citations

Colosia, Ann, Peter C. Trask, Robert Olivares, et al.. (2013). Efficacy and Safety Of Treatments For Relapsed Or Refractory DLBCL: Results Of a Systematic Literature Review. Blood. 122(21). 5104–5104. 1 indexed citations

Lee, Andrew, et al.. (2013). Epidemiologic model estimating number of Hodgkin lymphoma patients who relapsed after autologous stem cell transplant in the United States.. Journal of Clinical Oncology. 31(15_suppl). e12554–e12554. 1 indexed citations

Mehta, Jyotsna, et al.. (2012). Epidemiology of Myelofibrosis (MF), Polycythemia Vera (PV) and Essential Thrombocythemia (ET) in the European Union (EU). Blood. 120(21). 1744–1744. 5 indexed citations

Olivares, Robert, et al.. (2005). Evaluación de la mucosectomía circunferencial (PPH) en el tratamiento de la patología hemorroidal: experiencia U.C.. Revista Chilena de Cirugía. 57(3). 239–244. 1 indexed citations

10.

Pignon, Jean‐Pierre, Nathalie Syz, Marshall R. Posner, et al.. (2004). Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil–cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck. Anti-Cancer Drugs. 15(4). 331–340. 52 indexed citations

11.

Westphal, Manfred, Dana Hilt, Enoch Bortey, et al.. (2003). A phase 3 trial of local chemotherapy with biodegradable carmustine(BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology. 5(2). 79–88. 980 indexed citations breakdown →

12.

Bruno, René, Robert Olivares, J. Bérille, et al.. (2003). Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel.. PubMed. 9(3). 1077–82. 68 indexed citations

13.

Westphal, Manfred, Dana Hilt, Enoch Bortey, et al.. (2003). A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology. 5(2). 79–88. 67 indexed citations

14.

Posner, Marshall R., Bonnie S. Glisson, Gary Frenette, et al.. (2001). Multicenter Phase I-II Trial of Docetaxel, Cisplatin, and Fluorouracil Induction Chemotherapy for Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck. Journal of Clinical Oncology. 19(4). 1096–1104. 125 indexed citations

15.

Mattson, K., Johan Vansteenkiste, Roger Stupp, et al.. (2000). Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer. Anti-Cancer Drugs. 11(1). 7–13. 8 indexed citations

16.

Roszkowski, Kazimierz, A Płużańska, Maciej Krzakowski, et al.. (2000). A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer. 27(3). 145–157. 228 indexed citations

17.

Berlin, Ivan, Odile Spreux‐Varoquaux, Robert Olivares, et al.. (1995). A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers*. Clinical Pharmacology & Therapeutics. 58(4). 444–452. 121 indexed citations

18.

Berlin, Ivan, et al.. (1995). Monoamine oxidase A and B activities in heavy smokers. Biological Psychiatry. 38(11). 756–761. 110 indexed citations

19.

Girard, Pierre‐Marie, C. Gaudebout, Robert Olivares, et al.. (1993). Dapsone-Pyrimethamine Compared with Aerosolized Pentamidine as Primary Prophylaxis against Pneumocystis carinii Pneumonia and Toxoplasmosis in HIV Infection. New England Journal of Medicine. 328(21). 1514–1520. 149 indexed citations

20.

Olivares, Robert, Pierre Ducimetière, & Jean Claude. (1993). Monocyte Count: A Risk Factor for Coronary Heart Disease?. American Journal of Epidemiology. 137(1). 49–53. 185 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact